Segelmark Mårten, Hellmark Thomas, Wieslander Jörgen
Department of Nephrology, Lund University, Lund, Sweden.
Nephron Clin Pract. 2003;94(3):c59-68. doi: 10.1159/000072022.
The nephrotoxic potential of anti-glomerular-basement-membrane (GBM) antibodies has been demonstrated in numerous animal experiments. However, it is not known to what extent the properties of circulating anti-GBM antibodies in human disease reflect the severity of the disease and predict the outcome.
Clinical data were collected for 79 Swedish patients for whom a positive result had previously been obtained with anti-GBM ELISA. In stored sera from the patients, we measured antibody concentration, specificity and affinity together with antineutrophil cytoplasmic antibodies and alpha(1)-antitrypsin phenotype.
Six months after diagnosis, 27 (34%) were dead, 32 (41%) were on dialysis treatment and only 20 (25%) were alive with a functioning native kidney. The best predictor for renal survival was renal function at diagnosis. In patients who were not dialysis dependent at diagnosis however, renal survival was associated with a lower concentration of anti-GBM antibodies, a lower proportion of antibodies specific for the immunodominant epitope and the histological severity of the renal lesion. The only factor that correlated with patient survival was age.
Immunochemical properties of autoantibodies do not affect patient survival in anti-GBM disease but seem to be a factor in renal survival in patients detected before renal damage is too advanced.
抗肾小球基底膜(GBM)抗体的肾毒性潜力已在众多动物实验中得到证实。然而,尚不清楚人类疾病中循环抗GBM抗体的特性在多大程度上反映疾病的严重程度并预测预后。
收集了79名瑞典患者的临床资料,这些患者之前抗GBM酶联免疫吸附测定(ELISA)结果呈阳性。在患者储存的血清中,我们检测了抗体浓度、特异性和亲和力,以及抗中性粒细胞胞浆抗体和α1抗胰蛋白酶表型。
诊断后6个月,27例(34%)死亡,32例(41%)接受透析治疗,只有20例(25%)存活且自身肾脏功能正常。肾脏存活的最佳预测指标是诊断时的肾功能。然而,在诊断时不依赖透析的患者中,肾脏存活与抗GBM抗体浓度较低、针对免疫显性表位的抗体比例较低以及肾脏病变的组织学严重程度相关。与患者存活相关的唯一因素是年龄。
自身抗体的免疫化学特性不影响抗GBM病患者的存活,但似乎是在肾脏损害不太严重时检测出的患者肾脏存活的一个因素。